The mutations are far more likely if you give Regeneron to cancer patients and other immuno-compromised people. What an ethical problem... give a therapy knowin

The mutations are far more likely if you give Regeneron to cancer patients and other immuno-compromised people. What an ethical problem... give a therapy knowing that the therapy will kill off the virus identified by the therapy but with a higher chance that mutations in the patient become free to propagate, or don't administer the immuno-therapy to the most vulnerable people in an attempt to stem early mutation? Since only the rich are getting Regeneron, it really is a case of class warfare.